相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Letter
Psychiatry
Maria Sague et al.
SCHIZOPHRENIA RESEARCH
(2022)
Review
Pharmacology & Pharmacy
Selene R. T. Veerman et al.
Summary: The Dutch Clozapine Collaboration Group provides advice on managing clozapine-treated patients infected with or vaccinated against SARS-CoV-2. Patients on clozapine may have a higher risk of infection and complications from COVID-19, such as increased plasma levels of clozapine and decreased white blood cell counts. It is recommended to monitor clozapine plasma levels and adjust dosages accordingly, while considering reduction in dose during COVID-19.
PHARMACOPSYCHIATRY
(2022)
Review
Psychiatry
Christoph U. Correll et al.
Summary: People with schizophrenia have a significantly higher risk of premature death compared to the general population. This increased mortality risk is associated with factors such as suicide and natural causes. Antipsychotic medications, particularly second-generation long-acting injectable antipsychotics and clozapine, can reduce the risk of all-cause mortality in individuals with schizophrenia. Targeted treatment and early use of antipsychotics can help mitigate this mortality gap.
Article
Psychiatry
David Taylor et al.
Summary: The occurrence of agranulocytosis during clozapine treatment varies in severity, with some episodes being life-threatening while others are not. Monitoring schemes should focus on identifying true life-threatening agranulocytosis induced by clozapine.
Review
Medicine, General & Internal
Anum Iqbal Baig et al.
Summary: Clozapine, the only FDA-approved pharmacotherapy for treatment-resistant schizophrenia, is under-prescribed due to barriers related to provider knowledge, concerns about side effects, and poor adherence. Recommendations to overcome these barriers include improving prescriber education and training, utilizing interdisciplinary teams and integrated care, and simplifying blood test monitoring.
Article
Clinical Neurology
David Taylor et al.
Summary: This study shows that clozapine concentrations can be accurately measured at the point of care using capillary blood samples collected via a finger stick. There is a strong positive correlation between results from venous and capillary sampling methods, with minimal bias between standard assay and point-of-care testing.
JOURNAL OF PSYCHOPHARMACOLOGY
(2021)
Review
Psychiatry
Yutaro Shimomura et al.
Summary: Current guidelines and algorithms recommend increasing antipsychotic dose and switching to another antipsychotic, particularly clozapine, for treatment-resistant schizophrenia during the acute phase.
SCHIZOPHRENIA RESEARCH
(2021)
Article
Psychiatry
Ebenezer Oloyede et al.
Summary: Between 2002 and 2019, 115 patients were placed on CNRD, with 6% meeting FDA criteria for clozapine discontinuation. Among CNRD patients rechallenged with clozapine, 95% were successfully rechallenged, indicating that implementing updated FDA monitoring criteria in the UK may significantly reduce clozapine discontinuation due to hematological reasons.
SCHIZOPHRENIA BULLETIN
(2021)
Review
Psychiatry
Mattia Campana et al.
Summary: This systematic review and meta-analysis aimed to characterize ultra-treatment-resistant Schizophrenia patients and investigate the consistency in CRS definitions between studies. The results showed a large heterogeneity of CRS definitions and insufficient guidelines implementation. A new score modeled on a best practice definition was offered to help future trials increase their reliability.
SCHIZOPHRENIA RESEARCH
(2021)
Review
Psychiatry
Elias Wagner et al.
Summary: This study provides an updated review on the efficacy, tolerability, and management of clozapine in neuropsychiatric disorders, suggesting its superior overall efficacy in schizophrenia compared to other antipsychotics despite unfavorable adverse events. Further clinical studies and multidimensional side-effect management strategies are recommended to inform future guidelines.
TRANSLATIONAL PSYCHIATRY
(2021)
Article
Psychiatry
Elias Wagner et al.
SCHIZOPHRENIA BULLETIN
(2020)
Letter
Psychiatry
Jessica Nichols et al.
SCHIZOPHRENIA RESEARCH
(2020)
